PriceTargets.com logo

Cytosorbents - CTSO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.75
  • Forecasted Upside: 69.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.40 As of 03/24/2023 01:00 AM ET
▲ +0.08 (2.41%)

This chart shows the closing price for CTSO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytosorbents Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTSO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTSO

Analyst Price Target is $5.75
▲ +69.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cytosorbents in the last 3 months. The average price target is $5.75, with a high forecast of $6.00 and a low forecast of $5.50. The average price target represents a 69.12% upside from the last price of $3.40.

This chart shows the closing price for CTSO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Cytosorbents.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2023HC WainwrightReiterated RatingBuy$5.50Low
11/4/2022HC WainwrightLower TargetBuy$9.00 ➝ $5.50Low
5/4/2022B. RileyLower Target$7.00 ➝ $6.00High
3/10/2022B. RileyLower Target$10.00 ➝ $7.00Medium
10/14/2021B. RileyInitiated CoverageBuyHigh
10/13/2021CowenLower TargetOutperform$14.00 ➝ $10.00High
10/10/2021SVB LeerinkReiterated RatingBuyLow
8/4/2021HC WainwrightReiterated RatingBuy$13.00High
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$16.00 ➝ $17.00N/A
9/17/2020Jefferies Financial GroupInitiated CoverageBuy$15.00Medium
9/1/2020SVB LeerinkInitiated CoverageOutperform$15.00Medium
7/23/2020B. RileyReiterated RatingBuyLow
6/12/2020B. RileyInitiated CoverageBuy$16.00Medium
5/7/2020Maxim GroupInitiated CoverageBuy$14.00Low
5/6/2020HC WainwrightBoost TargetBuy$13.00 ➝ $14.00High
5/6/2020B. RileyBoost TargetBuy$12.00 ➝ $16.00High
4/16/2020HC WainwrightReiterated RatingBuy$13.00Low
3/26/2020Maxim GroupReiterated RatingBuy$8.00High
3/9/2020Dawson JamesReiterated RatingBuy$15.00 ➝ $17.00High
3/6/2020HC WainwrightReiterated RatingBuy$13.00Low
11/27/2019B. RileyReiterated RatingBuy$12.00Low
11/26/2019HC WainwrightReiterated RatingBuy$13.00High
11/25/2019Maxim GroupReiterated RatingBuy$8.00High
10/21/2019B. RileySet TargetBuy$10.00Low
8/7/2019HC WainwrightReiterated RatingBuyHigh
8/7/2019Maxim GroupSet TargetBuy$14.00High
7/19/2019B. RileySet TargetBuy$12.00N/A
5/8/2019Maxim GroupSet TargetBuy$14.00High
3/8/2019Maxim GroupReiterated RatingBuy$18.00High
3/8/2019HC WainwrightReiterated RatingBuy$15.00High
1/14/2019HC WainwrightSet TargetBuy$15.00High
12/20/2018Maxim GroupSet TargetBuy$10.00Low
11/7/2018HC WainwrightSet TargetBuy$15.00High
9/4/2018Maxim GroupReiterated RatingBuy$18.00Low
8/3/2018CowenReiterated RatingBuy$15.00High
5/15/2018Maxim GroupSet TargetBuy$13.00High
5/9/2018Maxim GroupSet TargetBuy$12.00High
5/9/2018HC WainwrightReiterated RatingBuy$14.00High
4/24/2018Maxim GroupSet TargetBuy$12.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
8/28/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 5 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cytosorbents logo
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
Read More

Today's Range

Now: $3.40
Low: $3.22
High: $3.46

50 Day Range

MA: $3.14
Low: $2.10
High: $4.17

52 Week Range

Now: $3.40
Low: $1.03
High: $4.59

Volume

58,629 shs

Average Volume

80,615 shs

Market Capitalization

$148.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytosorbents?

The following Wall Street sell-side analysts have issued research reports on Cytosorbents in the last year: B. Riley, HC Wainwright, and StockNews.com.
View the latest analyst ratings for CTSO.

What is the current price target for Cytosorbents?

2 Wall Street analysts have set twelve-month price targets for Cytosorbents in the last year. Their average twelve-month price target is $5.75, suggesting a possible upside of 69.1%. B. Riley has the highest price target set, predicting CTSO will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.50 for Cytosorbents in the next year.
View the latest price targets for CTSO.

What is the current consensus analyst rating for Cytosorbents?

Cytosorbents currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTSO will outperform the market and that investors should add to their positions of Cytosorbents.
View the latest ratings for CTSO.

What other companies compete with Cytosorbents?

Other companies that are similar to Cytosorbents include Health Sciences Acquisitions Co. 2, Nyxoah, Orchestra BioMed, KORU Medical Systems and DarioHealth. Learn More about companies similar to Cytosorbents.

How do I contact Cytosorbents' investor relations team?

Cytosorbents' physical mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company's listed phone number is (732) 329-8885 and its investor relations email address is [email protected] The official website for Cytosorbents is www.cytosorbents.com. Learn More about contacing Cytosorbents investor relations.